If you are diabetic then you know how it is to find beverages that actually taste good! It can be rather hard being diabetic at times fore it seems you sacrifice taste for diabetic friendly products. This is especially true when it comes to diabetic energy drinks.

Energy drinks, it seems, is a more and more important product in the lives of Americans. In the last five years this market has absolutely exploded. Unfortunately the market offered very little for sugar free energy drinks for the diabetics until now.

A cutting edge company called XS has come to the rescue of the diabetic crowd that wants the performance of energy drinks but doesn’t want the battery acid taste that conventional companies offer. XS offers more than twelve flavors that are 100% sugar free and most importantly great in taste. These flavors range from citrus, lemon, tropical, cran-grape, root beer, cola, black cherry cola, cherry, peach tea,?tea berry, and also host several caffeine free products as well.

Xs offers a beverage that has low carbs, no sugar, and a few calories, so it’s perfect for diabetics and even for those who want to lose weight, but still need that extra boost to help them. Since XS has zero sugar, the energy boost that XS gives people is from its blend of vitamins including B-12,B-6,B-3, and B-5. The B-12 is its main source of energy so you’ll get great performance and not have to worry about the crash effect afterward. In fact, XS’s B-12 is 4900% while red bull hosts only 73%. Obviously the difference is noticeable- not just in taste, but in performance.

XS comes in standard size energy drink cans and is sold by the case. There are 12 cans in each?case and every?case has a 90 day buy back guarantee. This means if you get your XS, try it, and are not satisfied with the flavor, you have 90 days to return the product with the pre-paid shipping label it comes with to get your complete refund- no questions asked. With 12 flavors, even if you don’t like on flavor, you are bound to like at least one.

?

If you are indeed diabetic and looking for an energy drink that gives you the boost you need and doesn’t taste horrible- you’ve found the drink you need. Don’t just take my word for it. Try it out yourself. You’ve got a full 90 day guarantee, so get a case, try one out- if you don’t like just send it back free of charge and you’ll get your money back as soon as it is received.

It’s not just some random fluke that you are reading this page- this product is what you have been searching for and I am confident that you will be 100% satisfied with it!

Combining pioglitazone with lifestyle modification does not enhance the efficacy of lifestyle modification alone for preventing Type 2 diabetes in Asian Indians with impaired glucose tolerance (IGT), show results from IDDP-2.

The thiazolidinediones have demonstrated efficacy for the primary prevention of diabetes in certain populations with IGT.

Ambady Ramachandran and colleagues (India Diabetes Research Foundation, Egmore, Chennai) have investigated whether combining pioglitazone with lifestyle modification would enhance the proven efficacy of lifestyle modification in preventing progression from IGT to Type 2 diabetes in Asian Indians, a population with several peculiarities in the clinical profile of diabetes.

As part of the Indian Diabetes Prevention Programme-2 (IDPP-2), 407 individuals with IGT received lifestyle modification plus pioglitazone 30 mg/day, or lifestyle modification plus placebo for 3 years. The primary outcome was development of Type 2 diabetes.

Writing in the journal Diabetologia, the authors report that pioglitazone did not enhance the effectiveness of lifestyle modification at reducing the number of Asian Indians with IGT who subsequently developed Type 2 diabetes.

The cumulative incidence of diabetes was 29.8% with pioglitazone and 31.6% with placebo (hazard ratio=1.084), a nonsignificant difference. Normoglycemia was achieved in 40.9% and 32.3% of participants receiving pioglitazone and placebo, respectively.

Although these results are at odds with studies such as ACT NOW (Actos Now for Prevention of Diabetes), which have shown a significant benefit for pioglitazone in reducing conversion of IGT to diabetes in a US population, they are in agreement with the results of IDDP-1, which showed that combining metformin and lifestyle modification did not have an added benefit.

The results of IDDP-2 have led the authors to suggest that pioglitazone does not reduce blood glucose in non-diabetic Asian Indians, but does reduce it in diabetic patients.

“It is probable that the lack of efficacy of pioglitazone noted in the present study may reflect an ethnic variation, which may relate to the differences in mechanisms of insulin resistance,” they conclude.

MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a part of Springer Science+Business Media. © Current Medicine Group Ltd; 2009

Free abstract

The UK National Institute for Health and Clinical Excellence (NICE) has recently updated their guidelines for the treatment of Type 2 diabetes to encompass new drugs that have been developed in recent years.

The first of these is the class of dipeptidyl peptidase (DPP)-4 inhibitors ??” vildagliptin and sitagliptin (currently approved in the UK), which act to stabilize concentrations of glucagon-like peptide and increase the secretion of insulin, say Amanda Adler (University of Cambridge, UK) and fellow authors of a summary of the new guidelines published in the British Medical Journal.

Other recently developed drugs approved for use in the UK include the glucagon-like peptide (GLP)-1 mimetic exenatide and the long acting insulin analogues insulin detemir and insulin glargine.

The guidelines recommend that clinicians should consider adding a DPP-4 inhibitor instead of a sulfonylurea to metformin if a patient’s blood glucose control becomes or remains inadequate after treatment with metformin plus a sulfonylurea (glycated hemoglobin [HbA1c] of 6.5% or higher), or if they cannot tolerate taking a sulfonylurea, for example due to renal impairment.

Due to the lower risk for hypoglycemia associated with these drugs, they are also recommended for use if a patient is at severe risk for hypoglycemia.

GLP-1 mimetics, such as exenatide, act by increasing insulin secretion, inhibiting glucagon secretion, and delaying gastric emptying. Unlike many other anti-diabetic drugs exenatide actually promotes weight loss.

The guidelines therefore recommend its use as a third line treatment for Type 2 diabetics taking metformin plus a sulfonylurea, particularly if they have a body mass index (BMI) of 35 kg/m² or above (Caucasians), as well as specific medical or psychological problems associated with high weight.

Exenatide is also suggested as an alternative to insulin in patients with a lower BMI if insulin use would have substantial occupational implications or if weight loss would have a beneficial effect on other obesity-related comorbidities.

The guidelines suggest that long-acting insulin should be considered for patients with recurrent symptomatic episodes of hypoglycemia, those who would otherwise need two injections of insulin per day plus oral drugs, and those who are unable to inject normal insulin themselves.

Recent safety concerns regarding the use of thiazolidinediones ??” rosiglitazone and pioglitazone ??” are addressed in the guidelines. Clinicians are advised not to prescribe thiazolidinediones if a patient has a high risk for heart failure or fracture. They are also advised to check their relevant regulatory body for up to date advice.

Most importantly: “Healthcare professionals caring for people with diabetes should consider their needs and preferences and give them the opportunity to make informed decisions about their care and treatment,” conclude Adler et al.

MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a part of Springer Science+Business Media. © Current Medicine Group Ltd; 2009

Free abstract

MedWire Links
NICE clinical guidelines update